• Species Reactivity

  Human

• Specificity

  Detects human Coagulation Factor VII in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human (rh) Kallikrein‑1, -2, -3,    
  -4, -5, -7, -8, -9, -10, -11, -12, -13, -14, -15, -B1, rhHGFA, rhFactor X, rhFactor XI, rhThrombin, rhuPA, or rhPROC is observed.

• Source

  Monoclonal Mouse IgG2b Clone # 321605

• Immunogen

  Mouse myeloma cell line NS0-derived recombinant human Coagulation Factor VII    
  Ala39-Pro444    
  Accession # NP_062562

• Formulation

  Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

• Label

  Alexa Fluor 750

Applications

• Recommended    
  Concentration

  Sample

• Flow Cytometry

  0.25-1 µg/10    ⁶ cells

  HASMC human aortic smooth muscle cells

• 
  

Please Note: Optimal dilutions should be determined by each laboratory for each application.  are available in the Technical Information section on our website.

Preparation and Storage

• Shipping

  The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

• Stability & Storage

  Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Background: Coagulation Factor VII

Coagulation Factors VII and VIIa refer to the pro and active forms of the same protease, respectively (1). Factor VII is synthesized in the liver and circulates in the plasma where it binds to tissue factor (TF), an integral membrane protein found in a variety of cell types. Upon binding of TF, Factor VII is rapidly converted into VIIa. The resulting 1:1 complex of VIIa and TF initiates the coagulation pathway and has also important coagulation-independent functions such as angiognesis (2). The cleavage and activation of Coagulation Factors VII, IX and X by VIIa:TF is phospholipid-dependent whereas the cleavage of small peptide substrates is not (1). The predominant splicing variant of Factor VII in normal liver corresponds to the 444 amino acid precursor (3, 4). After a signal peptide (residues 1-38), the mature chain can be further processed into the light chain (residues 39-190) and the heavy chain (residues 191-444). The purified rhFactor VII corresponds to the mature chain, which can be processed and activated by treatment with thermolysin and binding with rhTissue Factor (R&D Systems, Catalog # 2339-PA) under the conditions described above.

• References:

1. Morrissey, J.H. (2004) in Handbook of Proteolytic Enzymes, Barrett, A.J. et al. eds. p. 1659. 

2. Versteeg, H.H. et al. (2003) Carcinogenesis 24:1009.

3. Hagen, F.S. et al. (1986) Proc. Natl. Acad. Sci. USA 83:2412.

4. O’Hara, P.J. et al. (1987) Proc. Natl. Acad. Sci. USA 84:5158.

• Long Name:

  Coagulation Factor VII (Serum Prothrombin Conversion Accelerator)

• Entrez Gene IDs:

  2155 (Human); 14068 (Mouse)

• Alternate Names:

  coagulation factor VII (serum prothrombin conversion accelerator); Coagulation Factor VII; EC 3.4.21; EC 3.4.21.21; Eptacog alfa; F7; FVII coagulation protein; proconvertin; Serum prothrombin conversion accelerator; SPCA